Choosing Between GLP-1 Drugs: Liraglutide vs Exenatide for Type 2 Diabetes
Differential pharmacology comparison of liraglutide and exenatide for T2DM: liraglutide's once-daily dosing, greater HbA1c reduction, and more consistent weight loss versus exenatide's twice-daily profile.
Quick Facts
What This Study Found
Differential pharmacology comparison of liraglutide and exenatide for T2DM: liraglutide's once-daily dosing, greater HbA1c reduction, and more consistent weight loss versus exenatide's twice-daily profile.
Key Numbers
How They Did This
research study.
Why This Research Matters
Relevant for peptide research.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
Trust & Context
- Key Stat:
- Key finding Differential pharmacology comparison of liraglutide and exenatide for T2DM: liraglutide's once-daily dosing, greater HbA1c reduction, and more consist
- Evidence Grade:
- emerging evidence.
- Study Age:
- Published in 2010.
- Original Title:
- Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.
- Published In:
- Therapeutics and clinical risk management, 6, 401-11 (2010)
- Database ID:
- RPEP-01675
Evidence Hierarchy
Frequently Asked Questions
What was studied?
Choosing Between GLP-1 Drugs: Liraglutide vs Exenatide for Type 2 Diabetes
What was found?
Differential pharmacology comparison of liraglutide and exenatide for T2DM: liraglutide's once-daily dosing, greater HbA1c reduction, and more consistent weight loss versus exenatide's twice-daily profile.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01675APA
Pinkney, Jonathan; Fox, Thomas; Ranganath, Lakshminarayan. (2010). Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.. Therapeutics and clinical risk management, 6, 401-11.
MLA
Pinkney, Jonathan, et al. "Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.." Therapeutics and clinical risk management, 2010.
RethinkPeptides
RethinkPeptides Research Database. "Selecting GLP-1 agonists in the management of type 2 diabete..." RPEP-01675. Retrieved from https://rethinkpeptides.com/research/pinkney-2010-selecting-glp1-agonists-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.